Research Project Description:

This pioneering project is a public-private partnership formed by a multi-stakeholder consortium of 73 organizations; supported from the Innovative Health Initiative Joint Undertaking (IHI JU) and contributing industry partners from 18 countries. The aim of READI is to foster a more holistic, integrated system around clinical studies that will support the inclusion of patients usually underserved and underrepresented, and ultimately transform the way clinical studies are carried out in Europe. The project brings together experts from various fields, such as clinical studies, public health, multistakeholder collaboration, and patient engagement as well patient representatives themselves. One of the project’s first tasks will be to understand and characterise, at a country level, underserved and underrepresented populations in Europe and generate strategies to boost their involvement in clinical studies. Additionally, the project will co-create new methodological approaches, resources, training programs, and tools to design and conduct inclusive clinical studies. A key outcome of the project will be the development of an open, patient-centric digital platform for clinical studies. This innovative platform will bring together in one place resources, data, and information about clinical studies, driving the evolution of more inclusive clinical research. Finally, at least four clinical studies will be used to test the effectiveness of the tools and approaches developed. Ultimately, READI will usher in a more inclusive approach to conducting clinical trials, benefiting underserved and underrepresented groups and enhancing the quality of clinical research in Europe.

Principal Investigator(s) and Coordinating Institution(s):

  • SERMAS (Servicio Madrileño de Salud), through Hospital Universitario La Paz in Spain, Novartis in Switzerland, and supported by The Synergist in Belgium.

Researchers at University of Nicosia Medical School:

  • Prof Zoi Dorothea Pana, Department of Basic and Clinical Sciences

 **Other Researcher(s) Participating in the Project:

This pioneering project is a public-private partnership formed by a multi-stakeholder consortium of 73 organizations. The Consortium include:

AbbVie – Aarhus Universitet (AU) – Aarhus Universitetshospital (AUH) – Almirall SA (ALM) – AstraZeneca AB (AZ) – Boehringer Ingelheim – Breakthrough T1D (BREAKTHROUGH1D) – Bristol-Myers Squibb Company Corp (BMS) – CDISC Europe Foundation (CDISC) – Chiesi Group – Curewiki – Digestive Cancers Europe (DiCE) – Eli Lilly and Company (Lilly) – Esperity (CT.be) – European AIDS Treatment Group (EATG) – European University Cyprus (EUC) – ECRIN European Clinical Research Infrastructure Network (ECRIN) – F. Hoffmann-La Roche AG (Roche) – FIBHUG (Fundación para la Investigación Biomédica del Hospital Universitario de Getafe – Fundación para la Investigación Biomédica del Hospital Universitario la Paz (FIBHULP) – FISABIO (Fundacion para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana) – Forum des Patients Européens (EPF) – Fundación 29 de Febrero – Fundació Privada per a la Recerca i la Docència Sant Joan de Déu (FSJD) – GlaxoSmithKline Research & Development Limited (GSK) – Global Heart Hub (GHH) – HL7 International Fondation – Information Technology for Translational Medicine (ITTM) SA – Irish Platform for Patients’ Organisations Science and Industry (IPPOSI) – Janssen-Cilag Limited, a Johnson & Johnson company – Klinikum der Universität zu Köln (UHC) – Medicines and Healthcare Products Regulatory Agency (MHRA) – Midtjyllands EU Kontor Forening (CDEU) – National Cancer Institute (NCI) – National Institute for Health and Care Excellence (NICE) – Novo Nordisk A/S – Pagalbos Onkologiniams Ligoniiams Asociacija (POLA) – Penta Foundation (PENTA) – Pfizer Inc (Pfizer) – Sanofi – Shine 2Europe LDA (SHINE) – Socialit Software e Consulting Srl (SIT) – Stichting EUPATI Foundation (EUPATI) – Stichting VU – Synapse Research Management Partners SL (Synapse) – Synergist Services (Synerserv) – Takeda Pharmaceuticals International AG (TPIZ) – The August Pi i Sunyer Biomedical Research Institute (IDIBAPS) – Trial Nation (TrialNation) – UCB Biopharma (UCB) – Universitair Medisch Centrum Utrecht (UMCU) – University of Nicosia (UNIC) – University Court of the University of Aberdeen (UoA) – Vicomtech – ViiV Healthcare UK LTD – VU University Medical Center (VU) – Youth Cancer Europe (YCE) – Zabala Innovation Consulting SA (ZABALA) –

Research Project Acronym: READI IHI

UNIC Participating Institution: The UNIC Medical School is involved in the Research Proposal

Funding Agency: This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101166227. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Medicines and Healthcare Products Regulatory Agency and Breakthrough T1D. This project is also supported by UKRI (UK Research and Innovation).

Funding Programme:

  • IHI Innovative Health Initiative IHI – Call 4
  • Grant agreement number 101166227
  • Type of Action:  RIA (Research and Innovation Action)

UNIC/UNRF Budget: 200.000 euros

Total Research Project Budget:

  • EU funding: 31 538 000
  • Industry contribution: 34 822 875
  • Contributing partners: 500 000
  • Total approx. 66.8 millions euros

Research Project Status: Ongoing

Start and End Dates: 01/01/2025 – 31/12/2030 

Funding Programme and/or Research Project Logo:

Related Links:

*Related Conference Participations:

READI IHI Kick off meeting Madrid 2025(https://www.linkedin.com/posts/readi-project_official-launch-readi-project-activity-7285631895147601920-rBGT?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAt0wOABDB_H12YsRRINnYFCPDhHrFWFXus)